Orchid Pharma (LUX:ORCHP) Cyclically Adjusted Book per Share: $1.96 (As of Mar. 2026)


LUX:ORCHP Orchid Pharma Ltd LUX:ORCHP
60 GF Score
Price $5.45
GF Value $4.60
! 10 Warning Signs
View Full Analysis

What is Orchid Pharma Cyclically Adjusted Book per Share?

Orchid Pharma LUX:ORCHP 60 Cyclically Adjusted Book per Share is $1.96 as of Mar. 2026. GuruFocus rates LUX:ORCHP with a GF Score™ of 60/100 and a GF Value™ of $4.60. The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Orchid Pharma's adjusted book value per share for the three months ended in Mar. 2026 was $2.736. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.96 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Orchid Pharma's average Cyclically Adjusted Book Growth Rate was -6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-04), Orchid Pharma's current stock price is $5.45. Orchid Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $1.96. Orchid Pharma's Cyclically Adjusted PB Ratio of today is 2.78.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Orchid Pharma was 5.71. The lowest was 3.04. And the median was 4.18.


Orchid Pharma  (LUX:ORCHP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Orchid Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.45/1.96
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Orchid Pharma was 5.71. The lowest was 3.04. And the median was 4.18.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Orchid Pharma Cyclically Adjusted Book per Share Related Terms


Orchid Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma Cyclically Adjusted Book per Share Chart

Orchid Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.29 1.96

Orchid Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 0.00 1.37 0.00 1.96

LUX:ORCHP vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchid Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Orchid Pharma's Cyclically Adjusted PB Ratio falls into.


LUX:ORCHP
60GF Score
Orchid Pharma Ltd LUX:ORCHP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchid Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orchid Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.736/164.2724*164.2724
=2.736

Current CPI (Mar. 2026) = 164.2724.

Orchid Pharma Quarterly Data

Book Value per Share CPI Adj_Book
200903 1.760 56.615 5.107
201003 2.929 65.030 7.399
201103 3.380 70.768 7.846
201203 3.328 76.889 7.110
201209 0.000 82.244 0.000
201309 0.859 91.042 1.550
201603 -0.040 102.518 -0.064
201703 -0.797 105.196 -1.245
201709 0.000 109.021 0.000
201803 -1.368 109.786 -2.047
201809 -1.224 115.142 -1.746
201903 -1.139 118.202 -1.583
201906 0.000 120.880 0.000
201909 0.000 123.175 0.000
201912 0.000 126.235 0.000
202003 2.517 124.705 3.316
202006 0.000 127.000 0.000
202009 3.262 130.118 4.118
202012 0.000 130.889 0.000
202103 2.197 131.771 2.739
202106 0.000 134.084 0.000
202109 2.240 135.847 2.709
202112 0.000 138.161 0.000
202203 2.082 138.822 2.464
202206 0.000 142.347 0.000
202209 1.898 144.661 2.155
202212 0.000 145.763 0.000
202303 2.051 146.865 2.294
202306 0.000 150.280 0.000
202309 2.629 151.492 2.851
202312 0.000 152.924 0.000
202403 2.777 153.035 2.981
202406 0.000 155.789 0.000
202409 2.881 157.882 2.998
202412 0.000 158.323 0.000
202503 2.888 157.552 3.011
202506 0.000 159.755 0.000
202509 2.844 162.289 2.879
202512 0.000 163.281 0.000
202603 2.736 164.272 2.736

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.96 mean?
Orchid Pharma (LUX:ORCHP) has a Cyclically Adjusted Book per Share of $1.96 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's Cyclically Adjusted Book per Share too high?
Orchid Pharma's current Cyclically Adjusted Book per Share is $1.96. Overall, Orchid Pharma has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Orchid Pharma's Cyclically Adjusted Book per Share of $1.96 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current Cyclically Adjusted Book per Share is $1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Cyclically Adjusted Book per Share of $1.96. The stock's GF Value™ is $4.60, compared to a current price of $5.45 — trading 18.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.96. Orchid Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Cyclically Adjusted Book per Share is $1.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of $5.45 is trading 18.5% above its estimated GF Value™ of $4.60.

Key valuation signals for LUX:ORCHP:

  • Cyclically Adjusted Book per Share: $1.96
  • GF Value™: $4.60 vs. price of $5.45 (18.5% above fair value)
  • GF Score™: 60/100 with 10 warning signs

No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orchid Pharma Business Description

Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score

Get the complete analysis for LUX:ORCHP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.45
Price
$4.60
GF Value